|
Q1 FY2027
As of Sep 30, 2026
|
Q4 FY2026
As of Jun 30, 2026
|
Q3 FY2026
As of Mar 31, 2026
|
Q2 FY2026
As of Dec 31, 2025
|
Q1 FY2026
As of Sep 30, 2025
|
Q4 FY2025
As of Jun 30, 2025
|
Q3 FY2025
As of Mar 31, 2025
|
Q2 FY2025
As of Dec 31, 2024
|
Q1 FY2025
As of Sep 30, 2024
|
Q4 FY2024
As of Jun 30, 2024
|
Q3 FY2024
As of Mar 31, 2024
|
Q2 FY2024
As of Dec 31, 2023
|
Q4 FY2023
As of Jun 30, 2023
|
Q3 FY2023
As of Mar 31, 2023
|
Q2 FY2023
As of Dec 31, 2022
|
Q1 FY2023
As of Sep 30, 2022
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||
| Investments at fair value | ||||||||||||||||
| Control investments | ||||||||||||||||
| Non-controlled/affiliated | ||||||||||||||||
| Non-control/non-affiliate investments | ||||||||||||||||
| Total investments at fair value | ||||||||||||||||
| Cash and cash equivalents (restricted cash of $1,986 and $2,812, respectively) | ||||||||||||||||
| Receivables for: | ||||||||||||||||
| Interest, net | ||||||||||||||||
| Other | ||||||||||||||||
| Nonrelated Party | ||||||||||||||||
| Administration | ||||||||||||||||
| Affiliated Entity | ||||||||||||||||
| Derivative Assets, at fair value (Note 6) | ||||||||||||||||
| Deferred financing costs on Revolving Credit Facility (Note 4) | ||||||||||||||||
| Prepaid expenses | ||||||||||||||||
| Due from broker | ||||||||||||||||
| Total Assets | ||||||||||||||||
| Liabilities | ||||||||||||||||
| Notes | ||||||||||||||||
| Public Notes | ||||||||||||||||
| Prospect Capital InterNotes® | ||||||||||||||||
| Convertible Notes (less unamortized debt issuance costs of $0 and $649, respectively) (Notes 5 and 8) | ||||||||||||||||
| Revolving Credit Facility (Notes 4 and 8) | ||||||||||||||||
| Due to Prospect Capital Management (Note 13) | ||||||||||||||||
| Dividends payable | ||||||||||||||||
| Interest payable | ||||||||||||||||
| Due to broker | ||||||||||||||||
| Accrued expenses | ||||||||||||||||
| Other liabilities | ||||||||||||||||
| Nonrelated Party | ||||||||||||||||
| Administration | ||||||||||||||||
| Affiliated Entity | ||||||||||||||||
| Derivative Liabilities, at fair value (Note 6) | ||||||||||||||||
| Total Liabilities | ||||||||||||||||
| Preferred Stock, par value $0.001 per share (764,723,593 and 766,678,529 shares of preferred stock authorized; 67,450,547 and 68,468,200 issued and outstanding, respectively) (Note 9) | ||||||||||||||||
| Net Assets Applicable to Common Shares | ||||||||||||||||
| Common stock, par value $0.001 per share (3,235,276,407 and 1,233,321,471 common shares authorized; 536,295,785 and 512,746,556 issued and outstanding, respectively) (Note 9) | ||||||||||||||||
| Paid-in capital in excess of par (Notes 9 and 12) | ||||||||||||||||
| Accumulated other comprehensive income (loss) | ||||||||||||||||
| Distributions in excess of earnings (Note 12) | ||||||||||||||||
| Net Asset Value Per Common Share (Note 16) (in dollars per share) | ||||||||||||||||
Loading...